title: Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension.
abstract: Hypertension is associated with low plasma ascorbic acid levels and impaired endothelial function. Recent evidence suggests that increased vascular oxidative stress contributes to the pathophysiology of endothelial dysfunction and hypertension. We recently showed that chronic oral ascorbic acid therapy lowers blood pressure in hypertensive patients. We hypothesized that it would also improve endothelial vasomotor function. In a randomized, double-blind, placebo-controlled study, we examined the effect of acute (2 g po) and chronic (500 mg/day for 1 mo) ascorbic acid treatment on brachial artery flow-mediated dilation in 39 patients with hypertension. Compared with 82 age- and gender-matched normotensive controls, these patients had impaired endothelium-dependent, flow-mediated dilation of the brachial artery [8.9 +/- 6.1 vs. 11.2 +/- 5.7% (SD), P < 0.04]. After therapy, plasma ascorbic acid concentrations increased acutely from 50 +/- 12 to 149 +/- 51 micromol/l and were maintained at 99 +/- 33 micromol/l with chronic treatment (both P < 0.001). As previously reported, chronic ascorbic acid therapy reduced systolic and mean blood pressure in these patients. However, acute or chronic ascorbic acid treatment had no effect on brachial artery endothelium-dependent, flow-mediated dilation or on endothelium-independent, nitroglycerin-mediated dilation. These results demonstrate that conduit vessel endothelial dysfunction secondary to hypertension is not reversed by acute or chronic treatment with oral ascorbic acid. The effects of this treatment on resistance vessel vasomotor function warrant further investigation.
authors.affiliation: Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Duffy
authors.forename: N
authors.initials: N
authors.lastname: Gokce
authors.forename: M
authors.initials: M
authors.lastname: Holbrook
authors.forename: L M
authors.initials: LM
authors.lastname: Hunter
authors.forename: E S
authors.initials: ES
authors.lastname: Biegelsen
authors.forename: A
authors.initials: A
authors.lastname: Huang
authors.forename: J F
authors.initials: JF
authors.lastname: Keaney
authors.forename: J A
authors.initials: JA
authors.lastname: Vita
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage* / Q000378:metabolism; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000097:blood; D001916:Brachial Artery / Q000502:physiology; D015331:Cohort Studies; D006152:Cyclic GMP / Q000097:blood; D015777:Eicosanoids / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000975:Antioxidants; D015777:Eicosanoids; D009569:Nitric Oxide; D006152:Cyclic GMP; D001205:Ascorbic Acid